Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline

Victor Chedid, Priya Vijayvargiya, Michael Camilleri

Research output: Contribution to journalArticle

2 Citations (Scopus)
Original languageEnglish (US)
JournalClinical Gastroenterology and Hepatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

eluxadoline

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

@article{1c1b2f0402fb442bb41c09f5cac0c62a,
title = "Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline",
author = "Victor Chedid and Priya Vijayvargiya and Michael Camilleri",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cgh.2017.11.025",
language = "English (US)",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline

AU - Chedid, Victor

AU - Vijayvargiya, Priya

AU - Camilleri, Michael

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85040763184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040763184&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2017.11.025

DO - 10.1016/j.cgh.2017.11.025

M3 - Article

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

ER -